1. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513–21.
2. Kellogg International Working Group. The prevention of falls in later life. Danish Medical bulletin 1987; 34 (4): 1–24.
3. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003; 348: 42–9.
4. Nevitt MC, Cummings SR, Kidd S et al. Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 1989; 261: 2663–8.
5. Rubenstein IZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002; 18: 141–58.
6. Robinovitch SN, Inkster L, Maurer J et al. Strategies for avoiding hip impact during sideways falls. J Bone Miner Res 2003; 18: 1267–73.
7. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б и др. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии. 2002; 1: 8–11.
8. Dukas L, Schacht E, Runge M. Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis. J Osteoporos Int 2009.
9. Riefkohl EZ, Pharm D, Htather L et al. Medication and falls in the elderly: a review of the evidence and practical considerations. P&T 2003; 28 (11): 724–33.
10. Leipzig RM, Cumming RC, Tinneti ME. Drugs and falls in older people: a systematic review and meta-analysis. Part I. Psychotropic drugs. J Am Geriatr Soc 1999; 47: 30–9.
11. Leipzig RM, Cumming RC, Tinneti ME. Drugs and falls in older people: a systematic review and meta-analysis. Part II. Cardiac and analgetic drugs. J Am Geriatr Soc 1999; 47: 40–50.
12. Butt DA, Mamdani M, Austin PC et al. The risk of falls on initiation of antihypertensive drugs in the eldery. Osteoporos Int 2013.
13. Собченко К.Е., Скрипникова И.А., Новиков В.Е. и др. Изучение ассоциации антигипертензивной и липидснижающей терапии с костной массой в зависимости от факторов риска остеопороза. Кардиоваскулярная терапия и профилактика. 2013; 5: 49–55.
14. Фролова Е.В., Корыстина Е.М. Комплексная оценка состояния здоровья пожилого человека. Методические указания. СПб., 2013.
15. Oliver D, Connelly JB, Victor CR et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ 2007; 334: 82.
16. Lord SR, Sherrington C, Menz HB. Falls in older people: risk factors and strategies for prevention. Cambridge University Press, 2000.
17. Jackson C, Gaugris S, Sen SS et al. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. Q J Med 2007; 100: 185–92.
18. Tinetti ME, Baker DI, McAvay G et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331 (13): 821–7.
19. Haumschild MJ, Karfonta TL, Haumschild MS et al. Clinical and economic outcomes of fall-focused pharmaceutical intervention program. Am J Health Syst Pharm 2003; 60: 1029–32.
20. Lang T, Streeper T, Cawthon P et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment. J Osteoporos Int 2009.
21. Wang C, Swerdloff RS, Iranmanesh A et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal man. J Clin Endocrinol Metab 2000; 85: 2839–53.
22. Jackson C, Gaugris S, Sen SS et al. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. Q J Med 2007; 100: 185–92.
23. Dukas L, Bischoff HA, Lindpaintner LS et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230–6.
24. Richy F, Dukas L, Schacht E. Differential effects of D-Hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcific Tissue Int 2008.
25. Dukas L, Schacht E, Bischoff HA. Better functional mobility in community dwelling elderly is related to D-hormone and a minimal calcium intake of more than 512 mg/day. Osteoporos Int 2003; 14: S34.
26. Gallagher JC, Fowler SE, Detter JR. Combination treatment with estrogen and calcitriol in the prevention of age-relation bone loss. J Clin Endocrinol Metab 2001; 86: 3618–28.
27. Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 2004; 89–90: 497–501.
28. Ones K, Schacht E, Dukas L. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in poatmenopausal osteoporosis: a two-years randomized multiarm controlled trial. Inrernet J Endocrinol 2007: 4, published online.
29. Dukas L, Schacht E, Mazor Z et al. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 2005; 16: 198–203.
30. Orimo H. Clinical application of 1a(OH)D3 in Japan. Actual Rheumatol 1994; 89: 27.

И.А.Скрипникова

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва